Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist.
(2023) Journal of the European Academy of Dermatology and Venereology — Vol. 37, n° 1, p. e106-e109 (2023)
Files
2022-Fouarge-SuccessfultreatmentofpityriasisrubrapilariswithrisankizumabaIL23p19.pdf
Open Access - Adobe PDF
- 255.17 KB
Details
- Authors
de Montjoye, Laurence 
- Affiliations
Citations
Fouarge, A.-L., Cuvelier, M., Roquet-Gravy, C., de Montjoye, L., & Baeck, M. (2023). Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist. Journal of the European Academy of Dermatology and Venereology, 37(1), e106-e109. https://doi.org/10.1111/jdv.18516 (Original work published 2023)